Drug Search Results
More Filters [+]

Lipegfilgrastim

Alternative Names: lipegfilgrastim
Latest Update: 2024-05-14
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: G-CSF

Novel Mechanism: No

Modality: Peptide/Protein

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Chile | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Israel | Italy | Korea | Latvia | Lithuania | Luxembourg | Mexico | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Singapore | Slovakia | Slovenia | Spain | Sweden | Taiwan | Turkey | United Arab Emirates | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Teva
Company Location: PETACH TIKVA L3 49131
Company CEO: Kåre Schultz
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lipegfilgrastim

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Non-Small-Cell Lung Cancer|Lymphoma, Non-Hodgkin

Phase 3: Acute Respiratory Distress Syndrome|Neutropenia|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin

Phase 2: Lymphoma|Neutropenia|Multiple Myeloma|Sarcoma, Ewing|Rhabdomyosarcoma

Phase 1: Sarcoma, Ewing|Rhabdomyosarcoma|Pregnancy Outcomes|Neutropenia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2015-000087-34

P2

Completed

Rhabdomyosarcoma|Sarcoma, Ewing|Neutropenia

2019-01-08

SHEBA-14-1852-AN-CTIL

P2

Unknown status

Lymphoma|Multiple Myeloma

2018-07-01

AVOID Neutropenia

P3

Completed

Lymphoma, Non-Hodgkin|Acute Respiratory Distress Syndrome|Lymphoma, B-Cell

2018-04-24

2014-005096-85

P4

Completed

Non-Small-Cell Lung Cancer

2018-02-09

Recent News Events